This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

DDD Limited

94 Rickmansworth Road, Watford, Hertfordshire, WD18 7JJ
Telephone: +44 (0)1923 229251
Fax: +44 (0)1923 220728
WWW: http://www.dddgroup.co.uk
Medical Information Direct Line: +44 (0)1923 204492
Medical Information e-mail: customerdesk@dddltd.co.uk
Customer Care direct line: +44 (0)1923 229251
Medical Information Fax: +44 (0)1923 220728
Out of Hours Telephone: +44 (0)7581 572703

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 13/03/2012
SPC Blistex Cold Sore Cream


Go to top of the page
1. Name of the medicinal product

Blistex Cold Sore cream


Go to top of the page
2. Qualitative and quantitative composition

Each gram of cream contains 100 mg of docosanol.

Excipient: 50 mg propylene glycol/gram cream.

For a full list of excipients, see section 6.1


Go to top of the page
3. Pharmaceutical form

Cream

White cream


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Treatment of early stages (prodrome or erythema phase) of recurrent labial herpes simplex infection (cold sores) in immunocompetent adults and adolescents (over 12 years old).


Go to top of the page
4.2 Posology and method of administration

Route of Administration: Cutaneous use

Posology

Adults and adolescents (12-18 years): Apply a thin film carefully over the entire cold sore 5 times a day (approximately every 3 hours during waking hours).

Treatment must begin as soon as possible after the first cold sore symptoms or signs appear (pain, burning/itching/tingling or redness) as efficacy has not been demonstrated when the treatment is initiated at the stage of an already developed blister or ulcer.

Treatment should continue until healing has occurred, usually 4 to 6 days, or for a maximum of 10 days.

Elderly: No special dose recommendation.

Paediatric population

The safety and efficacy of Blistex Cold Sore cream in children aged younger than 12 years have not been established (see section 4.4).

Dosage in renal failure: No dose adjustments necessary due to negligible topical absorption.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance "docosanol" or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Avoid application close to or in the eyes.

This formulation contains propylene glycol and may cause skin irritation.

The cream should not be used in immunocompromised patients.

Treatment with the cream should not be initiated at the stage of an already developed blister or ulcer since no efficacy has been demonstrated at this point.

Paediatric population

There is no treatment experience available for the use in children below the age of 12 years and only limited experience in adolescent (aged 12-18 years). It is recommended that the cream should not be used in children under 12 years.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Therefore, Blistex Cold Sore cream should not be used simultaneously with other topical products (medicines, cosmetic products, creams) at the same application site.


Go to top of the page
4.6 Fertility, pregnancy and lactation

Fertility:

There are no adequate data from the use of docosanol on fertility in humans.

Pregnancy

There are no data from the use of docosanol in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Since systemic exposure to docosanol is negligible, docosanol can be used during pregnancy.

Lactation

There are no data from the use of docosanol in breast feeding women. No effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to docosanol is negligible. Docosanol can be used during breast-feeding.


Go to top of the page
4.7 Effects on ability to drive and use machines

Due to its negligible absorption docosanol has no influence on the ability to drive and use machines.


Go to top of the page
4.8 Undesirable effects

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

not known (cannot be estimated from the available data).

Results from clinical trials of the treatment of recurrent labial herpes simplex demonstrate no difference in the frequency or type of undesirable effects in patients treated with Blistex Cold Sore cream or placebo.

Nervous system disorders
Very common: Headache (10.4% of docosanol-treated patients and 10.7% of placebo-treated patients).

General disorders and administration site conditions
Common: Application site adverse reactions which include dry skin, rashes and skin disorders (2.9% of docosanol-treated patients and 2.3% of placebo-treated patients).

Facial oedema has also been reported but these application site adverse reactions are consistent with normal facial reactions experienced with cold sores.


Go to top of the page
4.9 Overdose

Adverse reactions related to overdose by topical application of Blistex Cold Sore cream are unlikely because of negligible percutaneous absorption. Similarly, poor oral absorption makes the occurrence of adverse reactions unlikely following ingestion of docosanol.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Chemotherapeutics for topical use, antivirals

ATC code: D06BB11

The exact mechanism of the antiviral activity of docosanol is unknown. In vitro studies indicate that docosanol affects the fusion between the virus and the plasma membrane, which inhibits intracellular uptake and replication of virus. In vitro studies demonstrate that docosanol-treated cells resist infection by lipid-enveloped viruses such as HSV-1. Docosanol has no effect against non-enveloped viruses.

Docosanol 10 % was compared to placebo (containing polyethylene glycol) in two randomised, double-blind, controlled clinical trials. In one study, 370 adults were randomised. Subjects started with treatment in the prodrome or erythema phase of an acute recurrence of orofacial herpes. The ITT population consisted of 183subjects for docosanol and 183 subjects for placebo. The median time to complete healing was 4.0 days in the docosanol group and 4.7 days in the placebo group a difference of 18.9 hours (p=0.0235; p=0.010 with covariate adjustment). In the second study, 373 adults were randomised. Subjects started with treatment in the prodrome or erythema phase of an acute recurrence of orofacial herpes. The ITT population consisted of 187 subjects for docosanol and 184 subjects for placebo. The median time to complete healing was 4.3 days in the docosanol group and 4.9 days in the placebo group a difference of 15.9 hours (p=0.1529; p=0,008 with covariate adjustment). In studies with treatment initiation at stages later than the prodromal or erythema stage, efficacy was not demonstrated.


Go to top of the page
5.2 Pharmacokinetic properties

Under conditions reflecting normal clinical use of Blistex Cold Sore cream, docosanol could not be quantified (limit of quantification, LOQ = 10 ng/ml) in the plasma of treated patients. Ten women with active labial herpes simplex were treated with Blistex Cold Sore cream. After a single dose on study day 1 and after multiple doses (five times daily, study days 2-3), blood samples were withdrawn up to 24 hours after treatment and analysed for docosanol. Of the 209 plasma samples analysed, the docosanol level was below the LOQ in 208 and exactly at the LOQ in one sample.

Docosanol is metabolized to docosanoic acid, its major metabolite. Both docosanol and docosanoic acid are endogenous components of cell membranes in man, particularly in erythrocytes, brain, nerve myelin sheath, lung, and kidney.


Go to top of the page
5.3 Preclinical safety data

Preclinical data revealed no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Sucrose stearates (mono and distearate)

Light mineral oil

Propylene glycol

Benzyl alcohol

Purified water


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

3 years.

After first opening the container: 6 months.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Epoxy-lined aluminium tubes closed with a LDPE screw cap.

Pack sizes: 2 g, 5 g, and 15 g

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. Marketing authorisation holder

DDD Limited

Watford

Hertfordshire

WD18 7JJ

United Kingdom


Go to top of the page
8. Marketing authorisation number(s)

PL 00133/0234


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

14 November 2003/14 November 2008


Go to top of the page
10. Date of revision of the text

13 October 2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/26145/SPC/


Active Ingredients/Generics